Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
- 20 April 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (18), 9964-9972
- https://doi.org/10.1073/pnas.1913633117
Abstract
Isocitrate dehydrogenase (IDH) mutation is a common genetic abnormality in human malignancies characterized by remarkable metabolic reprogramming. Our present study demonstrated that IDH1-mutated cells showed elevated levels of reactive oxygen species and higher demands on Nrf2-guided glutathione de novo synthesis. Our findings showed that triptolide, a diterpenoid epoxide from Tripterygium wilfordii, served as a potent Nrf2 inhibitor, which exhibited selective cytotoxicity to patient-derived IDH1-mutated glioma cells in vitro and in vivo. Mechanistically, triptolide compromised the expression of GCLC, GCLM, and SLC7A11, which disrupted glutathione metabolism and established synthetic lethality with reactive oxygen species derived from IDH1 mutant neomorphic activity. Our findings highlight triptolide as a valuable therapeutic approach for IDH1-mutated malignancies by targeting the Nrf2-driven glutathione synthesis pathway.Keywords
This publication has 54 references indexed in Scilit:
- β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomasProceedings of the National Academy of Sciences of the United States of America, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activationNature, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanismProceedings of the National Academy of Sciences of the United States of America, 2011
- High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial CancerCancer Research, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2Carcinogenesis: Integrative Cancer Research, 2008